Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Dec 02, 2020 10:43am
106 Views
Post# 32017567

RE:RE:RE:RE:Excerpts from the Final Prospectus dated Nov 26th

RE:RE:RE:RE:Excerpts from the Final Prospectus dated Nov 26thIchor also recently announced that it would be offering COVID-19 testing as part of an agreement with the State of Hawaii as well as initiate COVID-19 testing for travellers to China. StageZero’s relationship with Ichor means that StageZero will process these COVID-19 Tests for such travellers who request COVID-19 testing from Ichor.



Jonnyboy85 wrote: The Company also achieved the following during the third quarter: 


-Revenue increased more than four times the revenue of fiscal year 2019; 


-Received approximately US$1.5 million in cash which significantly exceeds projected operating costs of $900,000 per quarter;  


-Signed multiple new partners. These include a county in a US State affected by COVID-19, healthcare groups, and several travel groups with exposure to airlines;


-Granted preferred lab status by the Government of Barbados to conduct COVID-19 testing for tourists travelling by air into the country;


-Working with Ichor to process tests for players in the IIHF World Junior Championships;


-Extended agreements until year end with a number of partners; 


-Expanded testing options with nasal swabs and saliva tests as well as the respiratory panel (the respiratory panel will cost US$725 per test);  


-Hired additional staff and purchased equipment, test reagents, and consumable materials (for COVID-19 Tests and Aristotle®); and  


-Expanded laboratory footprint and automation in preparation for Aristotle® introduction.



Jonnyboy85 wrote: During the first six weeks of COVID-19 testing, StageZero performed approximately 5,000 COVID-19 Tests. To the end of October, StageZero had performed approximately 13,000 COVID-19 Tests. The initial orders StageZero entered into for COVID-19 testing was with five (5) client groups; it is now performing tests for approximately fifty (50) client groups and adding more. New groups are being added on an ongoing basis. StageZero anticipates increasing demand for testing over the next several months and through the winter as planned COVID-19 testing commences according to the timetables set by these client groups. The projected growth in COVID-19 testing is occurring and is on pace with StageZero’s expectations with significant growth anticipated on a quarter over quarter basis in order to meet the projected revenue. Testing revenue is therefore expected to show significant increases over consecutive quarters for the next three (3) to four (4) quarters.





Jonnyboy85 wrote: (currently, StageZero has testing supplies and inputs available to process approximately 30,000 COVID-19 Tests)



Jonnyboy85 wrote: The Company has received interest from the City of Alpharetta, Georgia, United States, Phlebfinders and UDoTest, among others, to have the Company provide COVID-19 Tests to their respective workforces, clients and residents. In addition, the Company is providing testing for the employees and court system of a large county in the United States, an airline, Ichor Blood Services Inc. (“Ichor”), a film company, urgent care centres, a global visa and travel group as well as a number of other groups


"The Company plans on introducing Aristotle® to the market by Q1 2021."

"As of October 2020, the Company’s testing capacity is in excess of 1,000 tests per day (comprising all types of COVID-19 Tests) and is trending towards 3,000 tests per day."

 

 




<< Previous
Bullboard Posts
Next >>